<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37550861</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2093-5978</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Endocrinology and metabolism (Seoul, Korea)</Title><ISOAbbreviation>Endocrinol Metab (Seoul)</ISOAbbreviation></Journal><ArticleTitle>Beyond Acute COVID-19: Investigating the Incidence of Subacute Thyroiditis in Long COVID-19 in Korea.</ArticleTitle><Pagination><StartPage>455</StartPage><EndPage>461</EndPage><MedlinePgn>455-461</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3803/EnM.2023.1711</ELocationID><Abstract><AbstractText Label="BACKGRUOUND">The correlation between acute coronavirus disease 2019 (COVID-19) and subacute thyroiditis (SAT) has not been clearly investigated in "long COVID" patients. We aimed to investigate the incidence of SAT during convalescence and after the acute phase of COVID-19, comparing with that of the general population.</AbstractText><AbstractText Label="METHODS">Data from a total of 422,779 COVID-19 patients and a control group of 2,113,895 individuals were analyzed. The index date was defined as the date 3 months after confirmation of COVID-19. The incidence rate (IR) of SAT and hazard ratios (HRs) were calculated per 100,000 persons. Subgroup analysis included analysis of HRs 90-179 and 180 days post-COVID-19 diagnosis; and additional analysis was conducted according to hospitalization status, sex, and age group.</AbstractText><AbstractText Label="RESULTS">The IR of SAT was 17.28 per 100,000 persons (95% confidence interval [CI], 12.56 to 23.20) in the COVID-19 group and 8.63 (95% CI, 6.37 to 11.45) in the control group. The HR of COVID-19 patients was 1.76 (95% CI, 1.01 to 3.06; P=0.045). The HR of SAT was 1.39 (95% CI, 0.82 to 2.34; P=0.220) up to 6 months after the index date and 2.30 (95% CI, 1.60 to 3.30; P&lt;0.001) beyond 6 months. The HR for SAT among COVID-19 patients was 2.00 (95% CI, 1.41 to 2.83) in hospitalized patients and 1.76 (95% CI, 1.01 to 3.06) in non-hospitalized patients compared to the control group. The IR of SAT was 27.09 (95% CI, 20.04 to 35.82) for females and 6.47 (95% CI, 3.34 to 11.30) for males. In the 19 to 64 age group, the IR of SAT was 18.19 (95% CI, 13.70 to 23.67), while the IR was 9.18 (95% CI, 7.72 to 10.84) in the 65 to 69 age group.</AbstractText><AbstractText Label="CONCLUSION">SAT could be a potential long-term complication of COVID-19. Long-term surveillance for thyroid dysfunction is needed especially in hospitalized, female and young-aged subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jeongmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Gi Hyeon</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Health Insurance Review and Assessment Service, Wonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Keeho</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Endocrinol Metab (Seoul)</MedlineTA><NlmUniqueID>101554139</NlmUniqueID><ISSNLinking>2093-596X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013968" MajorTopicYN="Y">Thyroiditis, Subacute</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Subacute</Keyword><Keyword MajorTopicYN="N">Thyroiditis</Keyword></KeywordList><CoiStatement>
<b>CONFLICTS OF INTEREST</b>
. No potential conflict of interest relevant to this article was reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>0</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37550861</ArticleId><ArticleId IdType="pmc">PMC10475963</ArticleId><ArticleId IdType="doi">10.3803/EnM.2023.1711</ArticleId><ArticleId IdType="pii">EnM.2023.1711</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  . Geneva: WHO; 2022. COVID-19 weekly epidemiological update, edition 115, 26 October 2022 [Internet] [cited 2023 Jul 11]. Available from:  https://apps.who.int/iris/handle/10665/363853.</Citation></Reference><Reference><Citation>Ziegler CG, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Tian Y, Li Z, Zhu J, Wei T, Lei J. Potential interaction between SARS-CoV-2 and thyroid: a review. Endocrinology. 2021;162:bqab004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953946</ArticleId><ArticleId IdType="pubmed">33543236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066521</ArticleId><ArticleId IdType="pubmed">32159775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazartigues E, Qadir MM, Mauvais-Jarvis F. Endocrine significance of SARS-CoV-2&#x2019;s reliance on ACE2. Endocrinology. 2020;161:bqaa108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454499</ArticleId><ArticleId IdType="pubmed">32652001</ArticleId></ArticleIdList></Reference><Reference><Citation>Duntas LH, Jonklaas J. COVID-19 and thyroid diseases: a bidirectional impact. J Endocr Soc. 2021;5:bvab076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135350</ArticleId><ArticleId IdType="pubmed">34189381</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Lin F, Tu W, Zhang J, Choudhry AA, Ahmed O, et al. Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19. Mol Cell Endocrinol. 2021;521:111097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709789</ArticleId><ArticleId IdType="pubmed">33278491</ArticleId></ArticleIdList></Reference><Reference><Citation>Boguslawska J, Godlewska M, Gajda E, Piekielko-Witkowska A. Cellular and molecular basis of thyroid autoimmunity. Eur Thyroid J. 2022;11:e210024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9142813</ArticleId><ArticleId IdType="pubmed">34981746</ArticleId></ArticleIdList></Reference><Reference><Citation>Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID-19: the THYRCOV study. Eur J Endocrinol. 2020;183:381&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494315</ArticleId><ArticleId IdType="pubmed">32698147</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanella L, Ruggeri RM, Ovcaricek PP, Campenni A, Treglia G, Deandreis D. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review. Clin Transl Imaging. 2021;9:233&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7950424</ArticleId><ArticleId IdType="pubmed">33728279</ArticleId></ArticleIdList></Reference><Reference><Citation>Naguib R. Potential relationships between COVID-19 and the thyroid gland: an update. J Int Med Res. 2022;50:3000605221082898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8894980</ArticleId><ArticleId IdType="pubmed">35226548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 &#x201c;long Covid&#x201d; patients and draft quality principles for services. BMC Health Serv Res. 2020;20:1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7750006</ArticleId><ArticleId IdType="pubmed">33342437</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ, Halim A, Halim M, Liu S, Aljeldah M, Al Shammari BR, et al. Inflammatory and vascular biomarkers in post-COVID-19 syndrome: a systematic review and meta-analysis of over 20 biomarkers. Rev Med Virol. 2023;33:e2424.</Citation><ArticleIdList><ArticleId IdType="pubmed">36708022</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  . Atlanta: CDC; 2022. Post-COVID conditions: CDC science [Internet] [cited 2023 Jul 11]. Available from:  https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-science.html.</Citation></Reference><Reference><Citation>Lui DT, Lee CH, Chow WS, Lee AC, Tam AR, Fong CH, et al. Insights from a prospective follow-up of thyroid function and autoimmunity among COVID-19 survivors. Endocrinol Metab (Seoul) 2021;36:582&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8258341</ArticleId><ArticleId IdType="pubmed">34107601</ArticleId></ArticleIdList></Reference><Reference><Citation>Korea Disease Control and Prevention Agency  . Cheongju: KDCA; 2023. Long COVID [Internet] [cited 2023 Jul 11]. Available from:  https://ncv.kdca.go.kr/hcp/page.do?mid=0102.</Citation></Reference><Reference><Citation>Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7:ofaa509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665635</ArticleId><ArticleId IdType="pubmed">33403218</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID-19. N Engl J Med. 2020;383:1757&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin T, Li Y, Ying Y, Luo Z. Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors. BMC Infect Dis. 2021;21:200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897883</ArticleId><ArticleId IdType="pubmed">33618678</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunada N, Honda H, Nakano Y, Yamamoto K, Tokumasu K, Sakurada Y, et al. Hormonal trends in patients suffering from long COVID symptoms. Endocr J. 2022;69:1173&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">35491089</ArticleId></ArticleIdList></Reference><Reference><Citation>Boaventura P, Macedo S, Ribeiro F, Jaconiano S, Soares P. Post-COVID-19 condition: where are we now? Life (Basel) 2022;12:517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9029703</ArticleId><ArticleId IdType="pubmed">35455008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn HY, Choi HS, Ha S, Cho SW. Incidence of subacute thyroiditis during the COVID-19 pandemic in South Korea using the National Health Insurance Service Database. Thyroid. 2022;32:1299&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">36047822</ArticleId></ArticleIdList></Reference><Reference><Citation>Domin R, Szczepanek-Parulska E, Dadej D, Ruchala M. Subacute thyroiditis: literature overview and COVID-19. J Med Sci. 2020;89:e472</Citation></Reference><Reference><Citation>Brancatella A, Viola N, Santini F, Latrofa F. COVID-induced thyroid autoimmunity. Best Pract Res Clin Endocrinol Metab. 2023;37:101742.</Citation><ArticleIdList><ArticleId IdType="pubmed">36813660</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A, et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 2020;8:739&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392564</ArticleId><ArticleId IdType="pubmed">32738929</ArticleId></ArticleIdList></Reference><Reference><Citation>Darvishi M, Nazer MR, Shahali H, Nouri M. Association of thyroid dysfunction and COVID-19: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2022;13:947594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9650069</ArticleId><ArticleId IdType="pubmed">36387848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui DT, Fung MM, Chiu KW, Lee CH, Chow WS, Lee AC, et al. Higher SARS-CoV-2 viral loads correlated with smaller thyroid volumes on ultrasound among male COVID-19 survivors. Endocrine. 2021;74:205&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8408037</ArticleId><ArticleId IdType="pubmed">34467467</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasiak M, Michalak R, Stasiak B, Lewinski A. Clinical characteristics of subacute thyroiditis is different than it used to be: current state based on 15 years own material. Neuro Endocrinol Lett. 2019;39:489&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">30860680</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasiak M, Lewinski A. New aspects in the pathogenesis and management of subacute thyroiditis. Rev Endocr Metab Disord. 2021;22:1027&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096888</ArticleId><ArticleId IdType="pubmed">33950404</ArticleId></ArticleIdList></Reference><Reference><Citation>Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The prevalence of autoimmune disorders in women: a narrative review. Cureus. 2020;12:e8094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292717</ArticleId><ArticleId IdType="pubmed">32542149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Yin J, Zhang M, Li J, Wu Y, Chen J, et al. Study on the clinical significance of ACE2 and its age-related expression. J Inflamm Res. 2021;14:2873&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8256825</ArticleId><ArticleId IdType="pubmed">34234512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui DT, Lee CH, Chow WS, Lee AC, Tam AR, Fong CH, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19. J Clin Endocrinol Metab. 2021;106:e926&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665541</ArticleId><ArticleId IdType="pubmed">33141191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui DT, Tsoi KH, Lee CH, Cheung CY, Fong CH, Lee AC, et al. A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors. Endocrine. 2023;80:380&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9810240</ArticleId><ArticleId IdType="pubmed">36596904</ArticleId></ArticleIdList></Reference><Reference><Citation>Monzani F, Caraccio N, Casolaro A, Lombardo F, Moscato G, Murri L, et al. Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful? Neurology. 2000;55:549&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10953190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisler A, de Seze J, Stojkovic T, Delisse B, Combelles M, Verier A, et al. Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand. 2003;107:154&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580868</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, et al. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Mult Scler. 2014;20:1265&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24515732</ArticleId></ArticleIdList></Reference><Reference><Citation>Watad A, David P, Brown S, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants and thyroid autoimmunity. Front Endocrinol (Lausanne) 2017;7:150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5256113</ArticleId><ArticleId IdType="pubmed">28167927</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>